Benutzerspezifische Werkzeuge

Information zum Seitenaufbau und Sprungmarken fuer Screenreader-Benutzer: Ganz oben links auf jeder Seite befindet sich das Logo der JLU, verlinkt mit der Startseite. Neben dem Logo kann sich rechts daneben das Bannerbild anschließen. Rechts daneben kann sich ein weiteres Bild/Schriftzug befinden. Es folgt die Suche. Unterhalb dieser oberen Leiste schliesst sich die Hauptnavigation an. Unterhalb der Hauptnavigation befindet sich der Inhaltsbereich. Die Feinnavigation findet sich - sofern vorhanden - in der linken Spalte. In der rechten Spalte finden Sie ueblicherweise Kontaktdaten. Als Abschluss der Seite findet sich die Brotkrumennavigation und im Fussbereich Links zu Barrierefreiheit, Impressum, Hilfe und das Login fuer Redakteure. Barrierefreiheit JLU - Logo, Link zur Startseite der JLU-Gießen Direkt zur Navigation vertikale linke Navigationsleiste vor Sie sind hier Direkt zum Inhalt vor rechter Kolumne mit zusaetzlichen Informationen vor Suche vor Fußbereich mit Impressum

Artikelaktionen

Publikationen

Ausgewählte Publikationen

Itaconate and derivatives reduce interferon responses and inflammation in influenza A virus infection. Sohail A, Iqbal AA, Sahini N, Chen F, Tantawy M, Waqas F, Winterhoff M, Ebensen T, Schultz K, Geffers R, Schughart K, Preusse M, Shehata M, Bähre H, Pils MC, Guzman CA, Mostafa A, Pleschka S, Falk C, Michelucci A, Pessler F. PLoS Pathog. 2022 Jan 13;18(1):e1010219. doi: 10.1371/journal.ppat.1010219. Online ahead of print.

Ancestral sequence reconstruction pinpoints adaptations that enable avian influenza virus transmission in pigs. Su W, Harfoot R, Su YCF, DeBeauchamp J, Joseph U, Jayakumar, Crumpton JC, Jeevan T, Rubrum A, Franks J, Pascua PNQ, Kackos C, Zhang Y, Zhang M, Ji Y, Bui HT, Jones JC, Kercher L, Krauss S, Pleschka S, Chan MCW, Webster RG, Wu CY, Van Reeth K, Peiris M, Webby RJ, Smith GJD, Yen HL. Nature Microbiology volume 6, pages 1455–1465 (2021). DOI: 10.1038/s41564-021-00976-y

Improved in vitro Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002 Hamza H, Shehata MH, Mostafa A, Pleschka S, Planz P. Front Microbiol. 2021; 12: 611958. Published online 2021 Feb 12. doi: 10.3389/fmicb.2021.611958

The rocaglate CR-31-B (−) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo. Müller C, Obermann W, Karl N, Wendel HG, Taroncher-Oldenburg G, Pleschka S, Hartmann RK, Grünweller A, Ziebuhr J. Antiviral Res. 2021 Feb; 186: 105012. Published online 2021 Jan 8. doi: 10.1016/j.antiviral.2021.105012

Combinatory Treatment with Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection. Schloer S, Goretzko J, Pleschka S, Ludwig S, Rescher U. Viruses. 2020 Jun 29;12(7):E703. doi: 10.3390/v12070703.

Transcriptome profiling and protease inhibition experiments identify proteases that activate H3N2 influenza A and influenza B viruses in murine airway. Harbig A, Mernberger M, Bittel L, Pleschka S, Schughart K, Steinmetzer T, Stiewe T, Nist A, Böttcher-Friebertshäuser E. J Biol Chem. 2020 Apr 17:jbc.RA120.012635. doi: 10.1074/jbc.RA120.012635.

Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model. Laure M, Hamza H, Koch-Heier J, Quernheim M, Müller C, Schreiber A, Müller G, Pleschka S, Ludwig S, Planz O. Antiviral Res. 2020 Jun;178:104806. doi: 10.1016/j.antiviral.2020.104806.

Influenza A Virus Infection Induces Apical Redistribution of Na+, K+-ATPase in Lung Epithelial Cells In Vitro and In Vivo. Peteranderl C, Kuznetsova I, Schulze J, Hardt M, Lecuona E, Sznajder JI, Vadász I, Morty RE, Pleschka S, Wolff T, Herold S. Am J Respir Cell Mol Biol. 2019 Sep;61(3):395-398. doi: 10.1165/rcmb.2019-0096LE.

Phosphoproteome Analysis of Cells Infected with Adapted and Nonadapted Influenza A Virus Reveals Novel Pro- and Antiviral Signaling Networks. Weber A, Dam S, Saul VV, Kuznetsova I, Müller C, Fritz-Wolf K, Becker K, Linne U, Gu H, Stokes MP, Pleschka S, Kracht M, Schmitz ML. J Virol. 2019 Jun 14;93(13):e00528-19. doi: 10.1128/JVI.00528-19

Time-Resolved Systems Medicine Reveals Viral Infection-Modulating Host Targets. Wiwie C, Kuznetsova I, Mostafa A, Rauch A, Haakonsson A, Barrio-Hernandez I, Blagoev B, Mandrup S, Schmidt HHHW, Pleschka S, Röttger R, Baumbach J. Syst Med (New Rochelle) 2019; 2(1): 1–9. Published online 2019 Mar 28. doi: 10.1089/sysm.2018.0013

Phosphoproteome Analysis of Cells Infected with Adapted and Nonadapted Influenza A Virus Reveals Novel Pro- and Antiviral Signaling Networks. Weber A, Dam S, Saul VV, Kuznetsova I, Müller C, Fritz-Wolf K4, Becker K, Linne U, Gu H, Stokes MP, Pleschka S, Kracht M, Schmitz ML. J Virol. 2019 Jun 14;93(13). pii: e00528-19. doi: 10.1128/JVI.00528-19.

Zoonotic Potential of Influenza A Viruses: A Comprehensive Overview.Viruses. Mostafa A, Abdelwhab EA, Mettenleiter TC, Pleschka S. Viruses. 2018 Sep 13;10(9):497. doi: 10.3390/v10090497.

NS Segment of a 1918 Influenza A Virus-Descendent Enhances Replication of H1N1pdm09 and Virus-Induced Cellular Immune Response in Mammalian and Avian Systems. Petersen H, Mostafa A, Tantawy MA, Iqbal AA, Hoffmann D, Tallam A, Selvakumar A, Pessler F, Beer M, Rautenschlein S, Pleschka S. Front Microbiol. 2018; 9: 526. Published online 2018 Mar 22. doi: 10.3389/fmicb.2018.00526

Targeting intracellular signaling as an antiviral strategy: aerosolized LASAG for the treatment of influenza in hospitalized patients. Scheuch G, Canisius S, Nocker K, Hofmann T, Naumann R, Pleschka S, Ludwig S, Welte T, Planz O. Emerg Microbes Infect. 2018; 7: 21. Published online 2018 Mar 7. doi: 10.1038/s41426-018-0023-3

Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase. Kuznetsova I, Arnold T, Aschacher T, Schwager C, Hegedus B, Garay T, Stukova M, Pisareva M, Pleschka S, Bergmann M, Egorov A. Mol Ther Oncolytics. 2017 Dec 15; 7: 37–44. Published online 2017 Sep 8. doi: 10.1016/j.omto.2017.09.002

Influenza A Virus Virulence Depends on Two Amino Acids in the N-Terminal Domain of Its NS1 Protein To Facilitate Inhibition of the RNA-Dependent Protein Kinase PKR. Schierhorn KL, Jolmes F, Bespalowa J, Saenger S, Peteranderl C, Dzieciolowski J, Mielke M, Budt M, Pleschka S, Herrmann A, Herold S, Wolff T. J Virol. 2017 May 15; 91(10): e00198-17. Prepublished online 2017 Mar 1. Published online 2017 Apr 28. doi: 10.1128/JVI.00198-17

Identification of specific residues in avian influenza A virus NS1 that enhance viral replication and pathogenicity in mammalian systems. Kanrai P, Mostafa A, Madhugiri R, Lechner M, Wilk E, Schughart K, Ylösmäki L, Saksela K, Ziebuhr J, Pleschka S. J Gen Virol. 2016 Sep;97(9):2135-48. doi: 10.1099/jgv.0.000542.

The Influenza A Virus Genotype Determines the Antiviral Function of NF-κB. Dam S, Kracht M, Pleschka S, Schmitz ML. J Virol. 2016 Aug 12;90(17):7980-90. doi: 10.1128/JVI.00946-16.

Macrophage-epithelial paracrine crosstalk inhibits lung edema clearance during influenza infection. Peteranderl C, Morales-Nebreda L, Selvakumar B, Lecuona E, Vadász I, Morty RE, Schmoldt C, Bespalowa J, Wolff T, Pleschka S, Mayer K, Gattenloehner S, Fink L, Lohmeyer J, Seeger W, Sznajder JI, Mutlu GM, Budinger GR, Herold S. J Clin Invest. 2016 Apr 1;126(4):1566-80. doi: 10.1172/JCI83931.

Efficient generation of recombinant influenza A viruses employing a new approach to overcome the genetic instability of HA segments. Mostafa A, Kanrai P, Petersen H, Ibrahim S, Rautenschlein S, Pleschka S. PLoS One. 2015 Jan 23;10(1):e0116917. doi: 10.1371/journal.pone.0116917. eCollection 2015.

In Silico Prediction and Experimental Confirmation of HA Residues Conferring Enhanced Human Receptor Specificity of H5N1 Influenza A Viruses. Schmier S, Mostafa A, Haarmann T, Bannert N, Ziebuhr J, Veljkovic V, Dietrich U, Pleschka S. Sci Rep. 2015 Jun 19;5:11434. doi: 10.1038/srep11434

Influenza virus-induced caspase-dependent enlargement of nuclear pores promotes nuclear export of viral ribonucleoprotein complexes. Mühlbauer D, Dzieciolowski J, Hardt M, Hocke A, Schierhorn KL, Mostafa A, Müller C, Wisskirchen C, Herold S, Wolff T, Ziebuhr J, Pleschka S. J Virol. 2015 Jun;89(11):6009-21. doi: 10.1128/JVI.03531-14.

Macrophage-expressed IFN-β contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. Högner K, Wolff T, Pleschka S, Plog S, Gruber AD, Kalinke U, Walmrath HD, Bodner J, Gattenlöhner S, Lewe-Schlosser P, Matrosovich M, Seeger W, Lohmeyer J, Herold S. PLoS Pathog. 2013 Feb;9(2):e1003188. doi: 10.1371/journal.ppat.1003188.

Reassortment of NS segments modifies highly pathogenic avian influenza virus interaction with avian hosts and host cells. Petersen H, Wang Z, Lenz E, Pleschka S, Rautenschlein S. J Virol. 2013 May;87(10):5362-71. doi: 10.1128/JVI.02969-12.

Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Droebner K, Pleschka S, Ludwig S, Planz O. Antiviral Res. 2011 Nov;92(2):195-203. doi: 10.1016/j.antiviral.2011.08.002.

Inhibition of influenza virus-induced NF-kappaB and Raf-MEK-ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. Pinto R, Herold S, Cakarova L, Hoegner K, Lohmeyer J, Planz O, Pleschka S. Antiviral Res. 2011 Oct;92(1):45-56. doi: 10.1016/j.antiviral.2011.05.009.

NS Reassortment of an H7-Type Highly Pathogenic Avian Influenza Virus Affects Its Propagation by Altering the Regulation of Viral RNA Production and Antiviral Host Response. Wang Z, Robb NC, Lenz E, Wolff T, Fodor E, Pleschka S. 2010. J Virol. Nov;84(21):11323-35

The NS-segment of an H5N1 highly pathogenic avian influenza virus (HPAIV) is sufficient to alter replication efficiency, cell tropism and host range of an H7N1 HPAIV. Ma W, Brenner D, Wang Z, Dauber B, Ehrhardt C, Högner K, Herold S, Ludwig S, Wolff T, Yu K, Richt JA, Planz O, Pleschka S. J Virol. 2010 Nov;84(21):11323-35. doi: 10.1128/JVI.01034-10.

Lung epithelial apoptosis in influenza virus pneumonia: The role of macrophage expressed TNF-related apoptosis-inducing ligand. Herold S. von Wulffen W. Steinmueller M. Pleschka S, Kuziel W.A., Seeger W. Maus UA, Lohmeyer J. J Exp Med. 2008 Dec 22;205(13):3065-77. doi: 10.1084/jem.20080201.

Higher polymerase activity of a human influenza virus enhances activation of the hemagglutinin-induced Raf/MEK/ERK signal cascade. Marjuki H, Yen HL, Franks J, Webster RG, Pleschka S, Hoffmann E. Virol J. 2007 Dec 5;4:134. doi: 10.1186/1743-422X-4-134.

Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calpha-mediated activation of ERK signaling. Marjuki H, Alam MI, Ehrhardt C, Wagner R, Planz O, Klenk HD, Ludwig S, Pleschka S. J Biol Chem. 2006 Jun 16;281(24):16707-15. doi: 10.1074/jbc.M510233200.

MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. Ludwig S, Wolff T, Ehrhardt C, Wurzer WJ, Reinhardt J, Planz O, Pleschka S. FEBS Lett. 2004 Mar 12;561(1-3):37-43. doi: 10.1016/S0014-5793(04)00108-5.

Influenza virus propagation is impaired upon specific inhibition of the Raf/MEK/ERK signaling cascade. Pleschka S, Wolff T, Ehrhardt C, Hobom G, Planz O, Rapp U, Ludwig S. Nat Cell Biol. 2001 Mar;3(3):301-5. doi: 10.1038/35060098.. featured in “Nature Views” and in “Science Now”

A plasmid based reversed genetics system for influenza A virus. Pleschka S, Jaskunas S R, Engelhardt O, Zürcher T, Palese P, García-Sastre A, 1996, J Virol. 1996 Jun;70(6):4188-92. doi: 10.1128/JVI.70.6.4188-4192.1996.